Photocure Future Growth

Future criteria checks 4/6

Photocure is forecast to grow earnings and revenue by 139.2% and 15.7% per annum respectively while EPS is expected to grow by 139.4% per annum.

Key information

139.2%

Earnings growth rate

139.4%

EPS growth rate

Pharmaceuticals earnings growth	19.6%
Revenue growth rate	15.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Nov 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:PHOO - Analysts future estimates and past financials data (NOK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	635	74	79	109	2
12/31/2024	527	7	1	31	2
12/31/2023	463	-9	-4	42	2
9/30/2023	462	-34	18	29	N/A
6/30/2023	462	-39	36	42	N/A
3/31/2023	418	-62	6	11	N/A
12/31/2022	393	-72	-6	-2	N/A
9/30/2022	383	-79	2	4	N/A
6/30/2022	364	-76	-16	-12	N/A
3/31/2022	354	-68	1	4	N/A
12/31/2021	361	-31	20	24	N/A
9/30/2021	364	7	191	29	N/A
6/30/2021	326	9	12	13	N/A
3/31/2021	290	10	9	11	N/A
12/31/2020	256	-22	14	16	N/A
9/30/2020	274	10	-134	35	N/A
6/30/2020	285	15	53	55	N/A
3/31/2020	284	19	37	39	N/A
12/31/2019	282	32	20	21	N/A
9/30/2019	216	-23	0	1	N/A
6/30/2019	199	-27	-15	-14	N/A
3/31/2019	192	-39	-23	-21	N/A
12/31/2018	182	-37	-26	-24	N/A
9/30/2018	171	-38	-31	-28	N/A
6/30/2018	162	-43	-46	-26	N/A
3/31/2018	156	-31	-46	-31	N/A
12/31/2017	151	-35	-42	-24	N/A
9/30/2017	150	-4	-7	19	N/A
6/30/2017	149	6	N/A	14	N/A
3/31/2017	145	29	N/A	18	N/A
12/31/2016	144	35	N/A	19	N/A
9/30/2016	140	8	N/A	-33	N/A
6/30/2016	141	3	N/A	-29	N/A
3/31/2016	140	-26	N/A	-18	N/A
12/31/2015	135	-36	N/A	-21	N/A
9/30/2015	126	-58	N/A	-22	N/A
6/30/2015	147	-29	N/A	8	N/A
3/31/2015	138	-23	N/A	1	N/A
12/31/2014	129	-25	N/A	-6	N/A
9/30/2014	129	-2	N/A	-21	N/A
6/30/2014	92	-39	N/A	-64	N/A
3/31/2014	89	-50	N/A	-92	N/A
12/31/2013	84	-59	N/A	-100	N/A
9/30/2013	105	-44	N/A	-54	N/A
6/30/2013	108	-51	N/A	-62	N/A
3/31/2013	117	-45	N/A	-53	N/A
12/31/2012	134	-30	N/A	-55	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHOO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: PHOO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PHOO is expected to become profitable in the next 3 years.

Revenue vs Market: PHOO's revenue (15.7% per year) is forecast to grow faster than the UK market (3.9% per year).

High Growth Revenue: PHOO's revenue (15.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHOO's Return on Equity is forecast to be high in 3 years time

Photocure Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Photocure ASA Reiterates Financial Guidance for the Year 2024

Recent updates

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Photocure ASA Announces Change of Board Composition

Less than half of directors are independent

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies